Search Results

We’re glad to have Peter's dedication, experience, and passion in building innovative therapeutics."

August 2022 "Geneva, Switzerland, August 18, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage

December 2021 "Geneva, Switzerland, December 17, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq:

July 2022 "Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 22, 2022 – Addex Therapeutics

Odorant G protein-coupled receptors as potential therapeutic targets for adult diffuse gliomas: a systematic Glioma is the most common adult malignant brain tumor and requires novel therapeutic strategies to improve genomic and transcriptomic profiles of ORs in glioma, we suggest that ORs are potential biomarkers and therapeutic

biggest opportunities will emerge: Building receptor-specific delivery systems for gene or peptide therapeutics

November 2021 "Nov. 15, 2021 LONDON – There’s not yet proof of the pudding, but Omass Therapeutics Ltd

June 2022 "G protein-coupled receptors (GPCRs) represent a major therapeutic target class as they play In 2019, 5 out of 20 first-in-class approved therapeutic agents targeted GPCRs.

Modulator Research Collaboration for Substance Use Disorders "Geneva, Switzerland, August 15, 2022 - Addex Therapeutics

Allosteric Modulator Pharmacology to Treat Dyskinesia and Other Movement Disorders with Tim Dyer Addex Therapeutics "Tim Dyer is the Co-Founder and CEO of Addex Therapeutics, which is focusing on the pharmacology known

Receptor 2 (CB2) is a G protein-coupled receptor (GPCR) with considerable, though as yet unrealised, therapeutic

Receptor 2 (CB2) is a G protein-coupled receptor (GPCR) with considerable, though as yet unrealized, therapeutic

Phase 1 studies in Japan with JNJ-40411813 (ADX71149) "Geneva, Switzerland, November 15, 2021 – Addex Therapeutics

Screening Platform Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 6, 2022 - Addex Therapeutics

Orchestrate the Interface between Health and Disease GPCRs arguably represent the most effective current therapeutic Given the tremendous success of GPCRs as therapeutic targets, considerable focus has been placed on the ability of these therapeutics to modulate diseases by acting at cell surface receptors. GPCR superstructures, termed receptorsomes, both at the cell surface membrane and in the intracellular domain

Nanobodies (Nbs), known as variable antigen-binding (VHH) domain or single-domain antibodies, are small the development of more selective drugs capable of modulating specific signaling pathways, improving therapeutic This allows for tailoring the half-life of nanobodies to increase their therapeutic window depending its conformation, protects the Schiff base, and prevents protein degradation, potentially offering therapeutic Nanobodies: A Review of Generation, Diagnostics and Therapeutics.

This dimerization allows the N-terminal activation domain of the receptor to repeatedly engage and disengage Additionally, the dimeric state allows rotational movement of the receptor's extracellular domain (ECD only enhances our understanding of class B1 GPCR biology but also opens new avenues for developing therapeutic Graaf, C., et al., Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic

and the complexity of the central nervous system (CNS) pose a challenge for developing successful therapeutics Emerging GPCR Therapeutic Targets in CNS Drug Discovery GPCRs have been studied for decades, but there Of the traditional GPCRs, CBRs are gaining ground as potential therapeutic targets in several CNS diseases One of the best tools to study therapeutic targets are fluorescent ligands , which are very useful in G-Protein-Coupled Receptors in CNS: A Potential Therapeutic Target for Intervention in Neurodegenerative

the initial GTP binding, the structures highlight critical shifts in the α5 helix and the α-helical domain The activation process begins with the α-helical domain (AHD) of the G protein in an open state, which puzzles and underscores the importance of understanding cellular processes at the molecular level for therapeutic

In less than a decade, nanobodies, or recombinant single-domain antibody fragments from camelids, have nanobodies with tailored specificities may expand the impact of these tools for both basic science and therapeutic

Adhesion GPCRs Piconewton Forces Mediate GAIN Domain Dissociation of the Latrophilin-3 Adhesion GPCR Unveiling Mechanical Activation: GAIN Domain Unfolding and Dissociation in Adhesion GPCRs GPCR Activation Tethered Ligands that Target the µ-Opioid Receptor Design and Synthesis of Novel GPR139 Agonists with Therapeutic

Discovery on Target’s 19th Annual GPCR-Based Drug Discovery Targeting G Protein-Coupled Receptors for New Therapeutic Modalities A quick revision of how β-adrenergic receptors work and how their antagonists can achieve therapeutic Domain Nominated for Prestigious Prix Galien USA ‘Best Startup’ Award: Pioneering GPCR-Driven Immunotherapies in Cancer Treatment Structure Therapeutics Appoints Angus C. Intracellular Allosteric Probe Selective optogenetic inhibition of Gαq or Gαi signaling by minimal RGS domains

GPCRs in Neuroscience G protein coupled receptors as targets for transformative neuropsychiatric therapeutics GPCRs in Oncology and Immunology CCR6 as a Potential Target for Therapeutic Antibodies for the Treatment Methods & Updates in GPCR Research Solvent accessibility of a GPCR transmembrane domain probed by in-membrane Inversago Pharma will present at BBHIC 2023 Orion Biotechnology attended the Swiss Biotech Day Addex Therapeutics GPCR Events, Meetings, and Webinars ASPET 2023 - American Society for Pharmacology and Experimental Therapeutics

When “inhibition” becomes activation—and how that insight fuels next-gen therapeutic design. Read the Feature ➤ Summer Days: Appetite, Suntans, and GPCR Micro-Domains Two recent papers connect ciliary Why micro-domains change what “global” signaling can and can’t explain.

September 2022 "The Smoothened receptor (SMO, a 7 pass transmembrane domain, Class F GPCR family protein In the absence of HH signaling, SMO is inhibited by Patched 1 (PTC1; a 12 pass transmembrane domain protein We are able to identify the interaction of membrane cholesterols with definite sites and domains within domain (CRD) and the intracellular domain (ICD), are through residues belonging to known cholesterol-binding Structural analysis of SMO domains shows significant changes in the CRD and ICD, during the course of

The TM helices 1–5 form a structurally conserved domain that facilitates the assembly of the helical and catalytic domains. Neutralization of the negatively charged extracellular pocket Ex1 destabilizes the cytosolic helical domain The TM domain acts as a functional component of Cya, guiding the assembly of the catalytic domain and

molecules because their large orthosteric peptide-binding pocket embedded deep within the transmembrane domain PTHR signaling that could be extended to GPCRs to expedite discoveries of small molecules as novel therapeutic

🎉 Conformational coupling between extracellular and transmembrane domains modulates holo-adhesion GPCR Pharmacology GPCR Jobs GPCR Molecular Pharmacologist Scientist - Biology Scientist I Cell Biology - Tectonic Therapeutic Structural Biologist Adhesion GPCRs Conformational coupling between extracellular and transmembrane domains

Congrats to the GPCR Therapeutics team for their recent paper in the American College of Clinical Pharmacology GPCR Symposium on 'GPCRs as Therapeutic Modalities'. GPCR Activation and Signaling Single-molecule analysis reveals that a glucagon-bound extracellular domain and oligomerization Molecular Insights into GPCR Mechanisms for Drugs of Abuse Industry News 'GPCR Therapeutics Nordisk to Acquire Inversago Pharma GPCR Events, Meetings, and Webinars NEW Antiverse: Reimagining Therapeutic

This week's highlights: Kudos to our partner, GPCR Therapeutics, for partnering with Bridge Biotherapeutics tANCHOR fast and cost-effective cell-based immunization approach with focus on the receptor-binding domain acids conjugation with [Cp*Rh(H2O)3]2+ by using the meta-dynamics/FMO3 approach Industry News GPCR Therapeutics - Providing the next generation of high-impact medicines Structure Therapeutics Provides Comprehensive Launches to Screen AI-Generated Virtual Libraries AbbVie to Acquire Cerevel Therapeutics in Transformative